The Role of Bioactive Compounds in the Prevention of Rheumatoid Arthritis

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: 15 July 2024 | Viewed by 1530

Special Issue Editor


E-Mail Website
Guest Editor
SPRINT Sport Physical Activity and Health Research & Innovation Center, Instituto Politécnico da Guarda, 6300-559 Guarda, Portugal
Interests: bioactive compounds; phytochemicals; natural products as health promoters; chronic diseases; circular economy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleagues,

Rheumatoid arthritis (RA) is a multifactorial disease that involves both genetic predisposition and environmental components. In 2019, there were 18 million RA patients worldwide. Aproximately 70% of RA patients are women, and 55% are older than 55 years. Thirteen million people with rheumatoid arthritis experience severity levels (moderate or severe) that could benefit from rehabilitation. RA is characterized by chronic inflammation of the synovial membrane that lines the joints, damage to the cartilage, and erosion of the bone. Bioactive compounds are dietary ingredients that provide beneficial health effects to functional foods and nutraceuticals. These compounds exhibit antioxidant and anti-inflammatory activities, as well as additional preventative properties. Bioactive compounds found in natural food products can control arthritic inflammation through multiple pathways, for example the inhibition of effector molecules (e.g., cytokines and chemokines), induction of anti-inflammatory mediators (e.g., IL-4, IL-10), regulation of the Th17/Treg balance, and modulation of osteo-immune cross-talk.

Dr. Luís Manuel Lopes Rodrigues Da Silva
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioactive compounds
  • functional foods
  • nutraceuticals
  • rheumatoid arthritis
  • anti-inflamatory activity
  • anti-inflammatory mediators

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2588 KiB  
Article
Medical Ozone: A Redox Regulator with Selectivity for Rheumatoid Arthritis Patients
by Olga Sonia León Fernández, Gabriel Takon Oru, Renate Viebahn-Haensler, Gilberto López Cabreja, Irainis Serrano Espinosa and María Elena Corrales Vázquez
Pharmaceuticals 2024, 17(3), 391; https://doi.org/10.3390/ph17030391 - 19 Mar 2024
Viewed by 779
Abstract
Rheumatoid arthritis (RA) and osteoarthritis (OA) are the most common arthritic diseases. Medical ozone has demonstrated its effectiveness in combination therapy with methotrexate or non-steroidal anti-inflammatory drugs for RA and OA, respectively. Although RA and OA have been compared from different points of [...] Read more.
Rheumatoid arthritis (RA) and osteoarthritis (OA) are the most common arthritic diseases. Medical ozone has demonstrated its effectiveness in combination therapy with methotrexate or non-steroidal anti-inflammatory drugs for RA and OA, respectively. Although RA and OA have been compared from different points of view, few studies have considered their redox status in spite of the oxidative processes that are involved in both diseases. The aim of this study was to compare RA with OA, evaluating their redox status and the effects of ozone on their clinical response to combined therapy with ozone. The redox status of 80 patients was determined: antioxidant defenses, injury markers, two subjective variables (pain and disability), and levels of antibodies against cyclic citrullinated peptides were evaluated. Oxidative stress and clinical response to combined therapy with ozone was higher than in the case of RA. After medical ozone treatment, there was an increase in antioxidant defense and a decrease in injury markers as well as pain, disability, and autoantibody concentrations. Redox biomarkers were able to differentiate between both arthritic diseases and combined therapy with ozone (methotrexate + ozone), showing a therapeutic selectivity for RA in comparison with OA. Full article
Show Figures

Figure 1

Back to TopTop